The UN World Health Agency (WHO) has recently recommended that COVVI-199 are published, but only for high-risk patients or who are seronegative.
CASIRIVIMAB and IMDEVIMAB (REGENERON) drugs are recommended on the one hand in “patients with non -severe forms of COVID who are at high risk of hospitalization”, such as the elderly as well as those with history or whose immune system is weakened, according to an opinion of experts from the World Health Organization (WHO) published in the medical journal “The BMJ”.
On the other hand, this treatment is recommended in patients affected “of a severe or critical form which are seronegative, that is to say which have not developed their own response in antibodies” despite the infection.
“For all other types of COVVI-19 patients, it is unlikely that the benefits provided by this antibody treatment is significant,” the WHO wrote in the press release.
